Michael Makris/LinkedIn
Nov 12, 2025, 04:42
Michael Makris on FDA Approval of GEVV-HEM Gene Therapy for Hemophilia
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”A biotechnology company (GeneVentiv Therapeutics) has received positive FDA feedback to develop their GEVV-HEM gene therapy for hemophilia.
This is AAV based gene therapy with human factor Va as the insert.
I will want a lot of animal data showing lack of thrombogenicity before human trials.”
Read the announcement here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?
-
Aug 26, 2026, 09:01Mary Cushman: The Role of IL-6 in Cardiovascular Disease
-
Aug 26, 2026, 07:49Linda Koch: Understanding Ageing Through Biological Transitions
-
Aug 26, 2026, 05:38Elias Lee։ Beyond MCA Stenosis – Recognizing Moyamoya
-
Aug 26, 2026, 03:46Hugo Ribeiro: Which NSAIDs Are Safest for Older Adults?
-
Aug 25, 2026, 19:45Cara T. Hoepner: Omega-3 is Not an Exposure